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valvular atrial fibrillation: do we apply the guidelines to elderly subjects?
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Introduction and Objectives: Atrial fibrillation (AF) is associated with a
five times higher risk of stroke mortality. The benefit of anticoagulants in this
context is widely recognized, particularly for older patients. Past studies show
reluctance to anticoagulate seniors because of their bleeding risk. The Euro-
pean guidelines are regularly updated to promote the prescription of anti-
coagulants in this population. The purpose of this study is to evaluate the type
and rate of antithrombotic prescription in real life in patients over 75 years
with a history of non-valvular AF.
Methods: This is a retrospective study performed in Nimes University
Hospital and Béziers Hospital. We studied 293 consecutive outpatients who
consulted their cardiologist between April and November 2012. The following
data were analyzed: CHA2DS2VASc score, HAS-BLED score, antithrombotic
therapy, type of AF, demographics.
Results: The mean age of patients is 82 years (+/-5.1 years, 75-99 years).
219 patients (74.7%) receive oral anticoagulants: 60.4% are treated with
vitamin K antagonists (VKA) and 14.3% with novel oral anticoagulants
(NOACs). 60 patients (20.6%) get aspirin or clopidogrel alone or in
various combinations, 14 patients (4.7%) receive no antithrombotic treatment.
The rate of anticoagulation (VKA or NOACs) decrease moderately with age:
81.5% (75-79 years), 75% (80-84 years) and 67% after 85 years. It is more
important in case of permanent AF (83%) versus paroxysmal (67%). Women
are less anticoagulated (67%) than men (82%).
Conclusions: A higher rate of anticoagulation is found in this elderly pop-
ulation compared with previous “real life” records. Anticoagulant therapy is
however less systematic in paroxysmal AF and women.
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Background: Platelet activation requires sweeping morphological
changes, supported by contraction and remodelling of platelet actin cytoskel-
eton. In epithelial and endothelial cells, AMP-activated protein kinase
(AMPK) controls actin cytoskeleton organization through the phorphorylation
of cytoskeletal targets, namely myosin regulatory light chains (MLC), cofilin
and the vasodilator-stimulated phosphoprotein (VASP), extending the role of
AMPK beyond metabolism.
Objectives: in this study, we hypothesized that AMPK was activated in
thrombin-stimulated platelets and played a role in platelet secretion, aggrega-
tion and clot retraction, by regulating polymerization and/or organization of
actin cytoskeleton through the phosphorylation of MLC, cofilin and VASP.
Results: Human platelets expressed exclusively the AMPKalpha1 isoform.
In human purified platelets, thrombin led to a transient activation of
AMPKalpha1 and to phosphorylation of its bona fide substrate, acetyl coA
carboxylase (ACC). Platelets isolated from mice lacking AMPKalpha1 exhib-
ited reduced aggregation and secretion response to thrombin, associated with
a defect in ACC, MLC, cofilin and VASP phosphorylation. These changes
were associated with an abrogration of thrombin-dependent F-actin formation.
Moreover, the percentage of platelets able to form lamellipodia after immobi-
lization on fibrinogen-coated coverslips and stimulation by thrombin, was sig-
nificantly reduced in the absence of AMPKalpha1, indicating an altered
cytoskeleton reorganization during spreading. More importantly, clot retrac-
tion was slower and less effective in KO platelets.
Conclusions: AMPKalpha1 plays a critical role in platelet function in
response to thrombin through the phrophorylation of cytoskeletal targets and
the subsequent regulation of cytoskeleton organization-dependent processes.
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Introduction: Several studies have indicated that impaired GFR is an
important predictor factor associated with impaired platelet inhibition by clop-
idogrel. In chronic kidney disease, the presence of low platelet inhibition by
clopidogrel is associated with adverse outcome following PCI and stenting. In
the present study, we sought to determine if renal transplantation per se alters
clopidogrel pharmacodynamics.
Patients and methods: 36 patients with kidney transplantation were
enrolled in one single center (Nephrology Department, Hôpitaux Universita-
ires de Strasbourg). Control patients were 126 patients with different degrees
of chronic renal failure, tested in the same conditions. Inclusion criteria were
patients under clopidogrel treatment of 75mg per day for at least 8 days.
Unstable patients or those presenting with any conditions that could account
for reduced platelet inhibition by clopidogrel (heart failure, shock) were
excluded. Treatment and medical history were collected at inclusion. Clopido-
grel pharmacodynamics was studied using the VASP assay.
Results: Patients with kidney transplantation were younger (58.3 vs
72.6 years, p<0.001), less likely diabetics (39% vs 57%, p=0.12), presented a
lower BMI (25.2 sv 27.2 p=0,05), the estimated glomerular filtration rate with
the MDRD formula is better (47.9 vs 39.5ml/mn/1.73m2, p=0.15), and there
is less inflammation. 89% patients in the transplantation group were under
anti-calcineurin and 50% under steroids at low dose. Platelet reactivity Index
a marker of the extent of P2Y12 inhibition was significantly higher in the
transplantation group vs controls (60.1% vs 51.2% p=0.014). By multivariate
analysis, high BMI and kidney transplantation were important predictors of
residual platelet reactivity under clopidogrel treatment. After adjustment on
eGFR with the MDRD formula, kidney transplantation remains an important
predictor of alter P2Y12 inhibition.
Conclusion: In kidney transplantation patients treated by clopidogrel,
impaired platelet inhibition exist, even after adjustment on estimated glomer-
ular filtration rate. The mechanisms by which immunosuppressive treatments
may alter clopidogrel pharmacodynamics requires further investigation
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inflammatory process and progressive endothelial damage in patients
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Aims: Endothelial dysfunction seems to play a pivotal role in atrial fibril-
lation (AF). The purpose of this study was to investigate the relationship
between AF and vascular endothelial growth factor (VEGF) and to investigate
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